Chandan Healthcare scaled its diagnostic franchise network to 500+ centres, reaching a total of 568+ centres. It targets 1,000 centres by FY27-end and 3,000 in two years.
Chandan Healthcare Ltd's board approved the appointment of an Independent Director, ratified cost auditor remuneration, and recommended varying the objects for utilising unutilised warrant proceeds.
Chandan Healthcare Limited announced the EGM voting results held on 29 August 2026. Shareholders approved the disinvestment of its entire shareholding in Chandan Pharmacy Limited.
Chandan Healthcare Limited held an EGM to approve the disinvestment of its entire stake in subsidiary Chandan Pharmacy Limited for approximately ₹16.77 Crore. This strategic divestment focuses resources on core diagnostics.
Chandan Healthcare is pivoting from pharmacy trading to a high-margin diagnostic-led strategy. The company reported healthy revenue growth but is over-relying on capital-light franchise scaling to drive future profitability.
Chandan Healthcare reported strong Q1 FY27 results with 19.62% YoY revenue growth and 42.27% EBITDA growth, driven by expansion into 15 states and diversified B2C, B2B, and B2G segments.
Chandan Healthcare Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of proceeds from its preferential issue.
Chandan Healthcare Limited scheduled a board meeting for August 14, 2026. The meeting will consider unaudited financial results for the quarter ended June 30, 2026.
Chandan Healthcare Limited received an Administrative Warning Letter from SEBI regarding disclosure lapses in its Red Herring Prospectus. No monetary penalty was imposed.
Chandan Healthcare approved the divestment of its entire 53.56% stake in Chandan Pharmacy to group company Chandan Hospital. The transaction is valued at ₹31.31 Crore.